IL2 and metastatic melanoma: The therapy entails initial lympho-depletion followed by administration of ex vivo expanded tumor infiltrating lymphocytes (TILs) and large doses of interleukin 2 (IL-2) and had an approximately 50% response rate in patients with highly advanced and metastatic melanoma [2, 3].